Search

Your search keyword '"Yuen, Yi Ching"' showing total 15 results
Start Over Author "Yuen, Yi Ching"
15 results on '"Yuen, Yi Ching"'

2. Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma

Author

de Mel, Sanjay, Rashid, Masturah B. M., Zhang, Xi Yun, Goh, Jasmine, Lee, Chun Tsu, Poon, Li Mei, Chan, Esther H. L., Liu, Xin, Chng, Wee Joo, Chee, Yen Lin, Lee, Joanne, Yuen, Yi Ching, Lim, Jing Quan, Chia, Burton K. H., Laurensia, Yurike, Huang, DaChuan, Pang, Wan Lu, Cheah, Daryl Ming Zhe, Wong, Esther Kam Yin, Ong, Choon Kiat, Tang, Tiffany, Lim, Soon Thye, Ng, Siok Bian, Tan, Soo Yong, Loi, Hoi-Yin, Tan, Lip Kun, Chow, Edward K., and Jeyasekharan, Anand D.

Published
2020
Full Text
View/download PDF

3. A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury

Author

Lee, Joanne, primary, Tabatabaeian, Hossein, additional, Poon, Michelle Limei, additional, Somasundaram, Nagavalli, additional, Xin, Liu, additional, Yuen, Yi Ching, additional, Teoh, Chia Meng, additional, Yan, Benedict, additional, Chan, Esther Hian Li, additional, Chee, Yen Lin, additional, De Mel, Sanjay, additional, Zhang, Bin, additional, Chew, Xiao Hong, additional, Tang, Tiffany, additional, Khor, Chiea Chuen, additional, Ngeow, Joanne Yuen Yie, additional, Ong, Choon Kiat, additional, Lim, Soon Thye, additional, Chng, Wee Joo, additional, Tai, E Shyong, additional, Ngiam, Kee Yuan, additional, Lee, Soo Chin, additional, Goh, Boon Cher, additional, Jeyasekharan, Anand Devaprasath D., additional, Tay, Yvonne, additional, and Aminkeng, Folefac, additional

Published
2022
Full Text
View/download PDF

4. Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study

Author

De Mel, Sanjay, primary, Goh, Jasmine, additional, Rashid, Masturah, additional, Hoppe, Michal, additional, Zhang, Xi Yun, additional, Jaynes, Patrick, additional, Ng, Esther KY, additional, Rahmat, Nur Atiqa Diana Binte, additional, Liu, Xin, additional, Poon, Michelle, additional, Chan, Hian Li Esther, additional, Lee, Joanne, additional, Chee, Yen-Lin, additional, Koh, Liang Piu, additional, Tan, Lip Kun, additional, Soh, Teck Guan, additional, Yuen, Yi Ching, additional, Loi, Hoi Yin, additional, Ng, Siok Bian, additional, Goh, Xueying, additional, Tan, Daryl, additional, Cheah, Daryl Ming Zhe, additional, Pang, Wan Lu, additional, Huang, Dachuan, additional, Somasundaram, Nagavalli, additional, Tang, Tiffany, additional, Chan, Jason Yongsheng, additional, Lim, Soon Thye, additional, Ong, Choon Kiat, additional, Chng, Wee Joo, additional, Chow, Edward KH, additional, and Jeyasekharan, Anand, additional

Published
2021
Full Text
View/download PDF

5. An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma.

Author

Goh, Jasmine, De Mel, Sanjay, Hoppe, Michal M., Mohd Abdul Rashid, Masturah Bte, Zhang, Xi Yun, Jaynes, Patrick, Ka Yan Ng, Esther, Rahmat, Nur'Atiqa Diana Binti, Jayalakshmi, Liu, Clementine Xin, Poon, Limei, Chan, Esther, Lee, Joanne, Chee, Yen Lin, Koh, Liang Piu, Tan, Lip Kun, Soh, Teck Guan, Yuen, Yi Ching, Loi, Hoi-Yin, and Ng, Siok-Bian

Subjects
NON-Hodgkin's lymphoma, COMBINATION drug therapy, B cells, DRUG efficacy, T cells, ALEMTUZUMAB
Abstract

Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin's lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical, and response rates remain poor in individuals with chemotherapy-resistant disease. Here, we evaluate an experimental-analytic method, quadratic phenotypic optimization platform (QPOP), for prediction of patient-specific drug combination efficacy from a limited quantity of biopsied tumor samples. In this prospective study, we enrolled 71 patients with RR-NHL (39 B cell NHL and 32 NK/T cell NHL) with a median of two prior lines of treatment, at two academic hospitals in Singapore from November 2017 to August 2021. Fresh biopsies underwent ex vivo testing using a panel of 12 drugs with known efficacy against NHL to identify effective single and combination treatments. Individualized QPOP reports were generated for 67 of 75 patient samples, with a median turnaround time of 6 days from sample collection to report generation. Doublet drug combinations containing copanlisib or romidepsin were most effective against B cell NHL and NK/T cell NHL samples, respectively. Off-label QPOP-guided therapy offered at physician discretion in the absence of standard options (n = 17) resulted in five complete responses. Among patients with more than two prior lines of therapy, the rates of progressive disease were lower with QPOP-guided treatments than with conventional chemotherapy. Overall, this study shows that the identification of patient-specific drug combinations through ex vivo analysis was achievable for RR-NHL in a clinically applicable time frame. These data provide the basis for a prospective clinical trial evaluating ex vivo–guided combination therapy in RR-NHL. Predicting possibilities with PDXs: Patients with non-Hodgkin's lymphomas (NHLs) often relapse after frontline treatment, and interpatient heterogeneity make personalized combination treatment difficult. Goh et al. have developed a hybrid experimental-analytic method that they call quadratic phenotypic optimization platform, or QPOP, to identify personalized drug combination therapies using ex vivo patient samples to improve patient outcomes. In a prospective cohort, physicians were able to alter treatment according to drug combinations identified using QPOP after 6 days to achieve complete responses in 5 of 17 patients with NHL. This is a promising step for providing new hope for patients who have relapsed NHL and provides a foundation for further clinical trials. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

9. A Non-Coding Variant in LOC105371512Confers Susceptibility to Bleomycin-Induced Lung Injury

Author

Lee, Joanne, Tabatabaeian, Hossein, Poon, Michelle Limei, Somasundaram, Nagavalli, Xin, Liu, Yuen, Yi Ching, Teoh, Chia Meng, Yan, Benedict, Chan, Esther Hian Li, Chee, Yen Lin, De Mel, Sanjay, Zhang, Bin, Chew, Xiao Hong, Tang, Tiffany, Khor, Chiea Chuen, Ngeow, Joanne Yuen Yie, Ong, Choon Kiat, Lim, Soon Thye, Chng, Wee Joo, Tai, E Shyong, Ngiam, Kee Yuan, Lee, Soo Chin, Goh, Boon Cher, Jeyasekharan, Anand Devaprasath D., Tay, Yvonne, and Aminkeng, Folefac

Published
2022
Full Text
View/download PDF

10. Immunophenotypic and Genetic Characteristics of Diffuse Large B-Cell Lymphoma (DLBCL), and Prognostic Significance of Cell of Origin (COO) in a Southeast Asian Cohort

Author

Chong, Vanessa CL, primary, Yap, Eng Soo, additional, Xin, Liu, additional, Chin, Suk Teng, additional, Jeyasekharan, Anand, additional, Chee, Yen-Lin, additional, Chan, Hian Li Esther, additional, De Mel, Sanjay, additional, Lee, Joanne Shu Xian, additional, Lee, Yee Mei, additional, Yuen, Yi Ching, additional, Koh, Liang Piu, additional, and Poon, Michelle, additional

Published
2018
Full Text
View/download PDF

11. Pharmacogenomic Prediction of Bleomycin-Induced Pneumonitis in South East Asian Hodgkin Lymphoma Patients

Author

Lee, Joanne Shu Xian, primary, Poon, Li Mei, additional, Liu, Xin, additional, Yuen, Yi Ching, additional, Somasundaram, Nagavalli, additional, Chin, Suk Teng, additional, Teoh, Chia Meng, additional, Yan, Benedict, additional, Chan, Hian Li Esther Hian Li, additional, Chee, Yen-Lin, additional, Tang, Tiffany, additional, Farzana, Noorul, additional, Aw, Caroline Hui Ting, additional, Khor, Chiea Chuen, additional, Ngeow, Joanne Yuen Yie, additional, Ong, Choon Kiat, additional, Tai, E Shyong, additional, Chng, Wee Joo, additional, Goh, Boon Cher, additional, Lee, Soo Chin, additional, and Aminkeng, Folefac, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results